due to the fact that urate and CKD share common downstream effectors, such as hypertension and chronic inflammation [3] [4] [5] . In contrast, kidney injury induced by uric acid has consistently been supported in experimental models through oxidative stress [6] , endothelial dysfunction [7] , renin-angiotensin system activation [8] and the triggering of epithelial-mesenchymal transition [9] . The uremic environment may further potentiate the nephrotoxic effect of hyperuricemia [10] . Several reviews have recently addressed the controversial role of uric acid in CKD populations [11, 12] ; however, only one metaanalysis study to date specifically evaluated the association between SUA levels and all-cause mortality, and found statistically significant indications of excess mortality among hyperuricemic CKD patients [13] .
Very few studies have used the longitudinal SUA trajectory in the course of CKD to evaluate the influence of SUA on the risk of progression to dialysis and mortality. In this study, we conducted a large registry-based CKD cohort study and took advantage of regular SUA and kidney function measurements to capture the SUA and estimated glomerular filtration rate (eGFR) trajectories, which allowed us to evaluate the associations between SUA trajectories and adverse outcomes of CKD.
M A T E R I A L S A N D M E T H O D S

Study population
In 2002, Taiwan's National Health Insurance launched the Project of Integrated Care of CKD and, since 2007, its focus has been on CKD stages 3b-5 [14] . This pre-end-stage renal disease (ESRD) program is a multidisciplinary approach (involving nephrologists, renal nursing specialists, pharmacists, health care educators and dieticians) to the design of individualized care plans for a wide range of CKD patients. The objective is to meet the therapeutic goals listed in the guidelines of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF/KDOQI) [14, 15] . China Medical University Hospital (CMUH) is a tertiary medical center in Central Taiwan, which joined the program in 2003. Consecutively, patients with CKD who were willing to participate were prospectively enrolled [16] . The CMUH pre-ESRD program currently includes more than 11 000 participants with an overall retention rate of 90%. CKD diagnoses were based on the working diagnosis of nephrologists or in accordance with the criteria outlined in the NKF/KDOQI Guidelines [15] . Patients in CKD stage 3b, 4 and 5 were, respectively, followed up at 12, 8 and 4 weeks, or when necessary. Biochemical markers of renal injury including serum creatinine, eGFR, SUA and the spot urine protein-creatinine ratio (PCR) were measured at intervals of no more than 12 weeks. All patients enrolled in the program were followed up until the initiation of maintenance dialysis (hemodialysis or peritoneal dialysis), loss to follow-up, death or 31 December 2015, whichever occurred first. Events of ESRD and mortality were verified by active contact and a review of electronic medical records (EMRs) in cases where patients were lost to follow-up for more than 6 months.
For more than a decade, CMUH has been using EMRs to facilitate care management. This made it possible to integrate data related to the CMUH pre-ESRD program with CMUH EMRs containing laboratory tests, medications, special procedures and admission records. Participants aged 20-90 years who were measured for SUA at least twice over a period of at least 6 months were then selected from this database. The index date was defined as the first day of pre-ESRD program enrollment. Patients were required to have undergone at least 6 months of continuous post-enrollment observation to allow sufficient follow-up for observation of the outcomes of interest, while also capturing a sample of sufficient size. We excluded patients aged less than 20 or over 90 years (n ¼ 168), those who had undergone dialysis (n ¼ 45), cases with illogical data entries (n ¼ 140) and those who did not undergo a sufficient number of SUA measurements (n ¼ 4834). This left a total of 5090 participants in the present study (Supplementary data, Figure S1 ). The study has been approved by the Big Data Center and the Research Ethical Committee/Institutional Review Board of CMUH (CMUH105-REC3-068).
Measurements of SUA level and kidney function
SUA levels were measured using the timed endpoint colorimetric method and creatinine levels were measured using the Jaffe rate method (kinetic alkaline picrate) at CMUH Central Laboratory using a Beckman UniCel V R DxC 800 (Beckman Coulter Inc., Fullerton, CA, USA). eGFR was estimated using the abbreviated Modification of Diet in Renal Disease equation [17] . Serum creatinine levels at enrollment were used to define the baseline eGFR and corresponding CKD stages using the cut-off values: >90, 60-89.9, 30-59.9, 15-29.9 and <15 mL/min/1.73 m 2 . All prospective SUA and eGFR measurements (until the endpoints) were taken into account. We calculated the quarterly average level of SUA in cases where the patient had more than one SUA within a 3-month period, and the SUA trajectory of each individual was modeled based on these serial quarterly average SUA measures (Figure 1 ). The same approach was applied to model the trajectory of eGFR (Supplementary data, Figure S2 ) and serum albumin (Supplementary data, Figure S3 ). Random spot urine dipstick and PCR measurements were used to quantify proteinuria. Proteinuria was defined as PCR !200 mg/g from random spot samples.
Other variables
Sociodemographic variables collected during the enrollment interview included age, sex, education, cigarette smoking and alcohol consumption. Smoking status was categorized as never, former and current. Alcohol consumption was categorized as never (<12 drinks in any 1 year in life), former (!12 drinks in any 1 year and not drinking now) and current (!12 drinks in any 1 year and currently drinking). Body mass index (BMI) was calculated as the patient's weight in kilograms divided by their height in meters squared. Baseline comorbidities, medication use including urate-lowering, glucose-lowering and antihypertensive agents, and relevant biochemical measures were compiled using registry data or information obtained from
EMRs within a 1-year window prior to enrollment. Indications of diabetes mellitus and hypertension were based on the clinical diagnosis of physicians using patient International Classification of Diseases codes and/or the use of glucoselowering/anti-hypertensive agents. A history of cardiovascular disease was defined as documented coronary artery disease, myocardial infarction, stroke or heart failure in EMRs.
Statistical analysis
General analysis. Continuous variables were expressed as median and interquartile range (IQR) and compared using the Kruskal-Wallis test. Categorical variables were expressed as frequency (percentage) and compared using the chi-square test. The associations among baseline SUA level, risk of ESRD and all-cause mortality were estimated by multivariable Cox regression analysis. Baseline SUA level was modeled as both a continuous and a categorical (quartiles) exposure. We characterized the dose-response relationship using a restricted cubic spline model with three knots located at the 10th, 50th and 90th percentiles of the overall SUA distribution. We then performed a two-stage analysis to evaluate the associations of SUA trajectories with the ESRD risk and all-cause mortality.
Stage 1: Identification of distinctive SUA and eGFR trajectories (pre-ESRD program enrollment to endpoints). Semi-parametric group-based trajectory modeling (GBTM) was used to characterize the trajectories of SUA and eGFR among patients enrolled in the CMUH pre-ESRD program throughout the follow-up period. Briefly, the PROC TRAJs macro (developed using SAS software) fits a semi-parametric mixture model to longitudinal data using the maximum-likelihood method [18] [19] [20] . This approach is useful when the number of subgroups and other information, such as the shape of trajectories in subgroups, are unknown. We empirically compared one-, two-, three-and four-group solutions and then optimized the number of subgroups using Bayesian Information Criterion values (close to zero indicating a good fit), wherein the shapes of trajectories were determined according to the order of the polynomial (linear, quadratic, cubic, etc.). The assignment of SUA and eGFR trajectory subgroups was determined by balancing clinical knowledge against latent hypotheses regarding the existence of distinct trajectories and their number or shape in order to facilitate meaningful interpretation. The determination of SUA and eGFR trajectories was performed prior to analysis pertaining to the risk of dialysis and mortality.
Stage 2: Association analysis between uric acid trajectories and the risk of dialysis and all-cause mortality. We evaluated the prospective relationships between SUA trajectories and the risk of dialysis and mortality using hazard ratios (HRs) with 95% confidence intervals (CIs) based on the Cox proportional hazards models. The models were adjusted hierarchically (see footnotes of Table 1 ). Considering the fact that renal function is a critical confounding factor pertaining to the influence of SUA levels on the risk of progression to dialysis and death, we formulated multiple domains of renal function including baseline eGFR, eGFR trajectories and primary etiologies of CKD (Supplementary data, Table S1 ) within a multivariable model to minimize residual confounding. Dose-response relationships for each uric acid trajectory were evaluated by examining HRs across trajectory groups, with significance evaluated through the testing of trajectory groups as a continuous variable. To characterize the risk of dialysis associated with SUA trajectories, we performed competing risk analysis in accordance with the methods outlined by Fine and Gray to minimize potential bias introduced by a competing risk of death [21] .
Exploratory subgroup analysis was used to evaluate effect modification in the adjusted models. Patients were stratified according to (i) age (65þ versus <65 years), (ii) gender, (iii) diabetes, (iv) hypertension and (v) the use of urate-lowering agents.
Several sensitivity analyses were conducted to evaluate the robustness of our findings (Supplementary data, Table S2 ). First, respectively extending the follow-up time to at least 1 year or 2 years produced consistent results. Second, adjusting baseline PCR levels and proteinuria status in the fully adjusted model did not alter the risk of progression to dialysis or mortality, despite a considerable reduction in the sample size. Even taking into account serum albumin measures as an additional adjustment for baseline level or trajectories defined by GBTM, we still obtained stable findings (Supplementary data, Table S2 ). Third, we described prescription trajectories of urate-lowering agents by modeling the probability trajectories of using uratelowering agents over the study period based on GBTM (Supplementary data, Figure S4 ). Further adjustment for prescription trajectories of urate-lowering agents did not change the clinical and statistical inference (Supplementary data, Table  S3 ). Fourth, the bidirectional relationships between SUA and eGFR trajectories observed in our study (data not shown) complicate the interpretation of the statistical findings, as eGFR trajectories may play a dual role as a confounder and also a mediator in the causal pathway between SUA trajectories and clinical outcomes of interest. We additionally presented a model that specifically adjusted for eGFR trajectories in the association analysis to help understand how the risk estimates change with 
R E S U L T S
Characteristics of various uric acid trajectories
Among the 5090 program participants, the median age at enrollment was 67.2 years (IQR: 56.8-75.9), the median followup time was 31.6 months and the median number of SUA measurements was 7 (IQR: 4-13). Four distinct SUA trajectories were identified (Figure 1 ) by GBTM. Two trajectories were persistently below the SUA concentration of 7.5 mg/dL, labeled as 'low' (trajectory 1, n ¼ 896, 17.6%) and 'moderate' (trajectory 2, n ¼ 2418, 49.7%), while the other two trajectories that stably exceeded 7.5 mg/dL were designated 'moderate-high' (trajectory 3, n ¼ 1485, 29.2%) and 'high' (trajectory 4, n ¼ 291, 5.7%). To further illustrate the longitudinal change of SUA in the four trajectory groups, we provide the distribution of all SUA measurements in each trajectory group and trajectory plots describing an individual's SUA measurements by SUA trajectory groups (one patient from each group) in the Supplementary data, Figure S5 .
From a demographic perspective, all of the participants presented similar levels of education and alcohol, regardless of their trajectories. Participants with 'high' and 'moderate-high' SUA trajectories tended to be younger at enrollment, male, a current or past smoker with a higher median BMI and in advanced CKD stage 4 or 5. As for comorbidities, diabetes and hypertension were prevalent among participants with 'high' and 'moderate-high' SUA trajectories, such that a corresponding number of individuals were exposed to anti-hypertensive medication (Table 2) . Participants with a 'high' trajectory were particularly likely to use allopurinol (25.8% versus 6.5% among stable low group) and/or colchicine (20.3% versus 11.1%) to control SUA levels. At enrollment, the median eGFR showed a gradual decline across the ascending SUA trajectories, as follows: low (40.5 mL/min/1.73 m ) (P for trend <0.001). A similar trend was observed in the levels of hemoglobin, serum sodium, calcium, albumin, high-density lipoprotein (HDL) across the SUA trajectories in ascending order; however, the opposite trend was observed in the level of serum creatinine, phosphate, lowdensity lipoprotein (LDL) and PCR across the SUA trajectories in ascending order (Table 2) .
Dialysis risk, all-cause mortality and SUA trajectories
During the 16 367 person-years of follow-up, 948 ESRD events and 472 deaths occurred. Among 948 ESRD events, the proportion of incident patients receiving hemodialysis or peritoneal dialysis was not different across the SUA trajectory groups (Table 2) . Incidental ESRD and all-cause mortality were 57.9 and 28.7 per 1000 person-years, respectively. For every mg/dL increase in baseline SUA, the adjusted risk of all-cause mortality increased by 8% (95% CI, 1-15%), but not of the risk of progression to dialysis. We found a significantly linear dose-response relationship between baseline SUA and the risk of progression to ESRD and all-cause mortality when not adjusting for baseline kidney function and eGFR trajectories ( Figure 2A1 and B1) . However, the dose-response curves flattened in the range of SUA level higher than 10 mg/dL after considering baseline eGFR and eGFR trajectories as covariates in the regression ( Figure 2A2-A3 and B2-B3) .
From the perspective of SUA trajectory, as illustrated by the Kaplan-Meier curve in Supplementary data, Figure S6 , participants with the 'high' trajectory of SUA had shorter dialysis-free survival and overall survival (log-rank test, P < 0.001). Compared with those with a 'low' SUA trajectory, the adjusted HR (95% CI) for incidental ESRD (Table 1) . We observed a similar association between SUA trajectories and incident ESRD and mortality with regard to age, gender, diabetes, hypertension and CKD stages (Figure 3) . Nonetheless, this association was modified by the use of urate-lowering agents and the risk of dialysis was attenuated among individuals receiving urate-lowering treatment within 1 year prior to enrollment (P-value for interaction ¼ 0.018).
D I S C U S S I O N
By taking advantage of the group-based trajectory model using serial SUA measurements among patients in the pre-ESRD program, we identified four distinct SUA trajectories since the program's initiation. Two of the trajectory groups showed high SUA concentrations consistently exceeding the conventional hyperuricemic cut-off of 7.5 mg/dL throughout the follow-up period, whereas the other two groups were consistently below the cut-off. Our findings indicate that SUA trajectory plays an important role in the progression to ESRD and all-cause mortality in an increasing dose-response pattern, following adjustments for baseline SUA, eGFR and the eGFR trajectory during follow-up. The results of this real-world observational study provide strong support for the assertion that SUA is a critical therapeutic target for the prevention of CKD progression and early mortality [22] . Furthermore, we found that only using baseline SUA is not sufficient to characterize the health hazards of chronic hyperuricemia in patients with CKD, as declining kidney function over the course of CKD may serve as both a mediator and also a confounder in the exposure-outcome pathway.
At present, the literature is somewhat inconclusive concerning the effects of SUA on kidney function. Most epidemiological studies on healthy adults have reported that SUA has harmful effects with regard to the development of CKD and the ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers; Ca, calcium; K, potassium; Na, sodium; P, phosphate; TCHO, total cholesterol. S U A t r a j e c t o r y p r e d i c t s E S R D a n d m o r t a l i t y i n C K D progression of CKD to ESRD [23] . Nonetheless, such an association has not been observed across the entire CKD population [11, 23] . As the failing kidney is associated with an increase in uric acid levels but also, in itself, has a decisive impact on the progression rate of kidney disease, it is challenging to evaluate the independent role of SUA on the risk of ESRD among CKD patients in epidemiological research. This is the first study to model the SUA trajectory in CKD patients. We also sought to minimize the potential residual confounding induced by the dynamics of kidney function during the follow-up period by adjusting for various matrices of kidney function including the eGFR trajectory. In recent studies using Mendelian randomization, a polymorphism (rs734553) of a gene that regulates the expression of a major tubular urate transporter (GLU9) predicts the progression to ESRD among CKD patients [24, 25] . As this risk allele indirectly represents the lifetime exposure to hyperuricemia, the findings provide a causal link between SUA and CKD progression, which are well in line with our results derived from longitudinal exposure data. The association of SUA levels with all-cause mortality among CKD patients remains an issue of contention. First, a significant association between SUA levels and all-cause mortality has not been identified consistently across studies [26] . Second, the shape of the effect direction of SUA has yet to be firmly established. U-shaped, J-shaped [27, 28] and even linear dose-response curves have been reported [13] . Interestingly, a reverse J-shaped relationship was reported in the ESRD population [29, 30] . Third, no previous study has sought to characterize the prospective trajectory of SUA among CKD patients. In this study, we observed a linear trend between the order of SUA trajectories and all-cause mortality. This effect was more pronounced among CKD patients without diabetes or hypertension. These findings demonstrate the need to evaluate the longitudinal effectiveness of urate-lowering agents in reducing the risk of mortality in CKD populations.
Only 31% of the patients were using urate-lowering agents at the time of enrollment in the pre-ESRD care program; however, the proportion was higher (40%) among those classified as 'high' trajectory. This is in line with the latest KDIGO clinical practice guidelines, in which the routine use of urate-lowering agents is not recommended for patients with asymptomatic hyperuricemia CKD [2] . However, in the present study, the use of urate-lowering agents within 1 year prior to enrollment was shown to attenuate the likelihood of progression to ESRD among individuals with high-increasing SUA trajectories. This observation is supported by two recent meta-analyses that showed the potential renoprotective effects of allopurinol [31, 32] . Nonetheless, the evidence is inconclusive, due to a lack of adequately powered randomized trials. Even if the causal claim is correct, there remains uncertainty with regard to the timing, the therapeutic target range and the safety of urate-lowering treatment in CKD populations.
An increase in triglycerides (TG) and a decrease in HDL were significantly correlated with high-increasing SUA trajectories. It is possible that hyperuricemic CKD patients have disturbed purine metabolism as well as deranged carbohydrate and lipid homeostasis [33] . Researchers have demonstrated a bidirectional link between TG synthesis and uric acid production [34] [35] [36] . Whether SUA could serve as an effective indicator of multiple metabolic derangements and how these metabolic derangements (in conjunction with SUA) influence the progression of CKD requires further investigation. Obesity and high dietary fructose may both serve as common denominators for a high TG/HDL ratio and high SUA levels; therefore, lifestyle modification and education against the overuse of fructose and the need for physical activity should be an integral aspect of comprehensive CKD care [37, 38] .
The strengths of this study include the careful minimization of exposure misclassification and confounding by kidney function, respectively, by modeling SUA trajectories and controlling baseline eGFR, primary etiologies, eGFR trajectories and proteinuria concomitantly. However, several limitations of this study should be taken into account. First, we lacked adherence patterns with which to evaluate the effectiveness of urate-lowering agents. Second, the threat of residual confounding can never be completely excluded in a nonrandomized study using registry-based EMRs. Information such as genetic data and dietary patterns, and environmental factors such as air pollution and metal exposure were not considered in this study. Also, adjustment was likely incomplete due to the residual confounding pertaining to the discrepancy between eGFR and measured (true) GFR, particularly in the pre-dialysis stage when sarcopenia may be at its worst [39] . However, our data reflect real-world practice and provide a longitudinal evaluation of the role of SUA in a CKD population. Third, missing data was a critical challenge in this prospective observational research. Nevertheless, frequent measurements of SUA and eGFR over long-term follow-up (median of seven measurements) minimized the likelihood of selective attrition bias that can be incurred by missing at random assumption. Similar results were observed when cohorts of patients with at least two to four SUA measurements available, in addition to the baseline SUA value for the full-model analysis, were considered (data not shown). Fourth, this study was performed at a single tertiary medical center, which may limit the generalizability of our findings. Nonetheless, biochemical and pathophysiological similarities across different populations enhance the validity of our findings. Fifth, mortality was ascertained using active surveillance rather than using the National Death Registry of Taiwan; however, two previous studies evaluating the effectiveness of pre-ERSD programs in Taiwan reported similar mortality rates [40, 41] .
In conclusion, the results of this study demonstrate the importance of SUA as a risk factor of all-cause mortality and progression to ESRD among CKD patients. Adequate experimental and empirical evidence is urgently required to assess whether SUA is an independent therapeutic target. Furthermore, researchers must determine the timing and means by which to 
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